Clinical Trial Detail

NCT ID NCT02335918
Title A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Celldex Therapeutics
Indications

colorectal cancer

ovarian cancer

lung non-small cell carcinoma

melanoma

head and neck squamous cell carcinoma

Therapies

Nivolumab + Varlilumab

Age Groups: adult

No variant requirements are available.